Multi-Modal Data, Multi-Omic Profiling and Multi-Model Architectures: The Future of Healthcare Technology

Nelson Advisors
1 hour ago
11 min read

Theoretical Foundations and Architectural Evolution of Healthcare AI

The landscape of biomedical research and clinical practice is undergoing a structural transition from isolated diagnostic paradigms to unified analytical frameworks. Historically, clinical evaluation relied on compartmentalised observations: radiologists interpreted morphological imaging, pathologists examined histological tissue slices, geneticists analysed targeted DNA sequences and primary care physicians reviewed narrative electronic health records (EHRs). While unimodal machine learning models achieved localised success within these specific domains, they fundamentally failed to capture the non-linear, cross-systemic interactions that characterise complex human pathologies.

The emergence of multimodal artificial intelligence addresses this limitation by synthesising heterogeneous data streams, encompassing genomic variants, transcriptomic profiles, proteomic abundances, metabolomic signatures, dynamic medical imaging, longitudinal EHRs and continuous sensor telemetry, into a singular predictive substrate. Integrating complementary clinical data modalities yields systemic diagnostic advantages.

Across scoping reviews of deep learning deployments in medicine, multimodal architectures consistently outperform their unimodal counterparts, achieving an average performance gain of 6.2 percentage points in the Area Under the Receiver Operating Characteristic Curve (AUC).

The methodological evolution of multimodal data fusion strategies can be delineated across three core architectural paradigms:

Concatenation-Based Integration (Early Fusion): Raw or preprocessed feature vectors from distinct modalities are stacked prior to model ingestion. While computationally straightforward, early fusion often suffers from high feature dimensionality, data sparsity, and the risk of subtle biological signals being masked by dominant high-volume modalities.
Predictive Aggregation (Late Fusion): Modality-specific models are trained independently, and their intermediate representations or output probability distributions are combined using meta-classifiers or decision rules. Although late fusion isolates modality-specific noise and accommodates asynchronously collected data across hospital departments, it inherently fails to model early cross-modal feature interactions.
Transformation-Based and Graph-Based Integration (Intermediate/Parallel Fusion): Advanced architectures project heterogeneous data types into a shared latent space or unified topological graph, allowing neural networks to model intra-modality and inter-modality dependencies simultaneously. Models employing graph convolutional networks (GCNs) and self-attention mechanisms operate at this layer, establishing feature-level biological interactions that exist independently of patient sample distribution.

This architectural progression is further augmented by the transition from task-specific models to broad multi-model ecosystems and Generalist Medical AI (GMAI) architectures. Pre-trained via self-supervision on massive, multi-institutional datasets, GMAI models leverage in-context learning to execute diverse clinical tasks, ranging from zero-shot disease risk stratification to multi-modality diagnostic reasoning, without requiring custom task-specific parameters or fine-tuning.

Single Cell Resolution and Multi-Omic Integration Frameworks

To comprehend the molecular mechanisms of complex pathologies such as cancer, neurodegeneration, and autoimmune dysfunction, machine learning systems must process biological phenomena across multiple biological strata. Mono-omics analysis provides a partial view of cellular regulation; single-cell multi-omics integration is required to reconstruct the complete cascade of information transfer from genome to epigenome, transcriptome, and proteome.

High-throughput single-cell assays simultaneously capture distinct cellular layers, generating multi-dimensional datasets that resolve tissue heterogeneity and trace cellular differentiation trajectories.

Modality / Method	Primary Biological Layers Measured	Technical Mechanism	Key Analytical Output
G&T-seq	Genomic DNA & mRNA Transcriptome	Physical separation of poly-A tail mRNA from genomic DNA within single cells prior to parallel sequencing.	Identifies cell-specific genomic copy number variations (CNVs) and direct transcriptomic consequences.
DR-seq	Genomic DNA & mRNA Transcriptome	Quenched gDNA and mRNA amplification protocols without physical cell separation.	Maps intra-tissue genetic heterogeneity directly to functional cellular gene expression profiles.
CITE-seq	Surface Proteome & mRNA Transcriptome	Oligonucleotide-barcoded antibody conjugation targeting cell-surface epitopes combined with single-cell RNA-seq.	Resolves surface protein expression alongside full transcriptomic profiles, overcoming post-transcriptional disconnects.
REAP-seq	Cell-Surface Proteins & mRNA Transcriptome	Uses antibody-conjugated small polymer tags paired with high-throughput microfluidic single-cell sequencing.	Measures protein abundance and RNA expression levels in parallel to elucidate post-transcriptional regulatory mechanisms.
TEA-seq	Targeted Epitranscriptome & Transcriptome	Targeted enzymatic amplification of specific RNA modifications combined with single-cell sequencing modalities.	Elucidates localized epitranscriptomic modifications and their precise regulatory influence on mRNA transcription dynamics.
ASAP-seq	Nascent mRNA & Transcription Rates	Rapid quantification of newly synthesized single-stranded adenine-rich transcript populations.	Quantifies real-time transcriptional bursts and kinetics at individual cellular resolution.

Integrating these omics streams requires neural architectures capable of navigating extreme data imbalance, feature redundancy and complex non-linear interactions. Supervised classification and subtyping frameworks have advanced beyond basic dimensionality reduction. Cancer Integration via Multi-kernel Learning (CIMLR) combines kernel-based learning algorithms to integrate genomic, epigenomic and transcriptomic matrices, enabling accurate survival rate prediction and molecular subtype segregation.

Similarly, the Multi-Omics Graph Convolutional Network (MOGONET) utilises omics-specific GCNs to learn intra-omics feature representations independently, projecting these embeddings into a View-Correlation Discovery Network (VCDN) to uncover cross-omics label correlations. Other models like MoGCN apply autoencoders for early fusion before projecting merged representations into a sample-similarity GCN, while SUPREME trains isolated GCNs on modality-specific patient networks before integrating latent embeddings to mitigate noise transfer.

Addressing a core limitation of sample-similarity GCNs, their inability to capture direct feature-to-feature molecular interactions, the SynOmics framework operates directly in feature space. SynOmics constructs intra-omics feature graphs alongside cross-omics bipartite networks, deploying a parallel learning architecture that simultaneously models within-modality and across-modality feature dependencies at every neural layer.

Complementing omics integration frameworks, specialised foundational models pre-trained on vast genomic sequences treat nucleotide sequences as complex languages, learning regulatory codes, non-coding variant impacts and chromatin accessibility directly from raw DNA and RNA.

Model Name	Parameter Scale	Architecture Base	Training Data Corpus	Core Capability / Application
DNABERT	86M – 89M	Transformer Encoder	Human Reference Genome	K-mer tokenization for gene promoter identification and transcription factor binding prediction.
DNABERT2	117M	Efficient Transformer	135 Species Genomes	Multi-species cross-genomic contextual embedding and variant effect prediction.
Enformer	23M	CNN + Transformer	Human and Mouse Genomes	Long-range genomic sequence processing for gene expression and chromatin state prediction.
HyenaDNA	Variable (1k–1M context)	Hyena Long Conv Operator	Human Reference Genome	Sub-quadratic processing of ultra-long genomic sequences up to 1 million tokens at single-nucleotide resolution.
EpiGePT	71.3M	CNN + Transformer	Human Genome + Transcription Factors	Epigenomic signal prediction and cell-type-specific gene expression modeling.
Evo	7B	Striped Hyena Operator	Prokaryotic, Viral, & Plasmid Genomes	Multi-scale biological generation, predicting DNA, RNA, and protein function from molecular sequences.
Evo2	1B / 7B / 40B	Striped Hyena 2 Operator	128,000 Genomes (Eukarya, Prokarya, Archaea)	Pan-genomic representation learning, zero-shot variant evaluation, and synthetic biological design.

Multi-Model Systems, Medical Foundation Models and Knowledge Graph Reasoning

Combining multi-omic data with spatial medical imaging and unstructured EHR narratives requires multi-model architectures capable of explicit biological reasoning. Geometric deep learning, multimodal vision-language models and mixture-of-experts paradigms represent key developments in this domain.

A major application of graph foundation models is zero-shot drug repurposing across large disease networks. The TxGNN architecture demonstrates this approach, addressing the challenge of identifying therapeutic options for diseases with limited molecular understanding or no existing treatments. Pre-trained on a clinical knowledge graph connecting 17,080 recognised diseases and 7,957 therapeutic candidates alongside biological entities such as genes, proteins, pathways and phenotypes, TxGNN formulates drug discovery as a zero-shot link prediction task. The model projects diseases, drugs, and biological targets into a low-dimensional latent space that preserves the topological geometry of the knowledge graph.

To infer candidates for diseases lacking established treatments, TxGNN deploys a metric learning module that calculates relational similarity across disease neighborhoods. This enables the model to transfer mechanistic therapeutic rationales from well-characterized, treatable conditions to novel or neglected disease profiles without requiring parameter updates or fine-tuning. Under zero-shot benchmark evaluations, TxGNN achieves a 49.2% improvement in indication prediction accuracy and a 35.1% improvement in contraindication identification over baseline algorithms.

Real-world validation demonstrates that TxGNN's zero-shot therapeutic rankings align with off-label prescribing patterns observed across healthcare systems. To enable clinical adoption, TxGNN incorporates an explainer module that extracts multi-hop paths through the knowledge graph, providing clinicians with interpretable rationales grounded in biological mechanisms.

Beyond graph neural networks, multimodal foundation models extend natural language architectures to interpret medical vision and multi-omic data.

Model Framework	Primary Modalities	Underlying Base Models	Architectural & Training Characteristics
LLaVA-Med	Clinical Language, Medical Vision (X-ray, MRI, CT, Histology, Pathology)	LLaVA, Vicuna/LLaMA, CLIP ViT	Fine-tuned on biomedical visual-instruction datasets; links radiological and histological features with conversational diagnostic reasoning.
MedVInT	Language, Radiologic & Pathologic Imaging	PMC-CLIP, PMC-LLaMA	Integrates specialized biomedical visual encoders with domain-adapted LLMs to execute visual question answering and diagnostic synthesis.
MedSAM	Multi-Modal Medical Image Segmentation	Segment Anything Model (SAM) core	Trained on 1.57 million image-mask pairs across 10 imaging modalities and over 30 cancer types; provides zero-shot anatomical and lesion segmentation.
COMPASS	Spatial Transcriptomics, Tumor Microenvironments, Text	Pan-Cancer Graph Foundation Model	Predicts patient-specific immune checkpoint inhibitor responses by integrating single-cell spatial microenvironments with tumor genomic profiles.
ATHENA	Clinical Records, Pharmacological Databases, Text	Reinforcement Learning Agent + Tool API Network	Executes multi-step treatment reasoning across FDA-approved therapeutics by querying 212 specialized biomedical databases.

Valuations of multimodal foundation models (e.g., GPT-4V, GPT-5, o3, MedGemma) reveal a strong dependency on textual prompt context during diagnostic image interpretation. When presented with visual diagnostic tasks containing minimal clinical text, vision-language models frequently display degraded performance.

However, when provided with expanded clinical text contexts, their diagnostic accuracy increases substantially; for example, model accuracy on specific visual tasks rises from 70% on low-text prompts to 90% on high-text prompts. This contrast indicates that current multimodal models excel at contextual information synthesis rather than isolated visual pattern recognition.

To operationalise these large-scale systems, specific deep learning components are dynamically combined:

Convolutional Neural Networks (CNNs): Architectures such as VGG19 serve as standard feature extractors for medical radiomics and spatial histopathology.
Recurrent Neural Networks (RNNs): Retain contextual memory across sequential time steps, making them suited for processing dynamic, longitudinal EHR streams, wearable biosensor telemetry and dynamic transcriptomic shifts.
Mixture of Experts (MoE): MoE architectures address the computational load of processing multimodal inputs by replacing dense neural layers with specialised sub-networks ("experts") managed by dynamic routing mechanisms. In healthcare applications, distinct experts specialise in processing specific data streams, such as dynamic electrophysiological signals, spatial transcriptomics, or unstructured clinical text, scaling total parameter capacity while managing inference costs.

Enterprise Infrastructure, Federated Frameworks and National Deployments

Translating multimodal, multi-omic, multi-model AI into operational clinical environments requires scalable data management architectures, federated integration systems and dynamic regulatory governance.

Traditional relational database management systems struggle with the high dimensionality and scale of biomedical datasets. Modern multimodal infrastructure increasingly relies on data platforms optimised for multi-dimensional arrays and high-throughput ingestion.

For example, platforms built on multi-dimensional array structures (such as TileDB) store complex datasets, including population-scale whole genome sequences, spatial transcriptomics, single-cell matrices, and volumetric medical imaging, as uniform multi-dimensional arrays. This array-based representation facilitates parallel querying, reduces data redundancy, and accelerates data loading into deep learning frameworks. Similarly, specialised medical imaging platforms (such as Flywheel) automate the ingestion, de-identification and annotation of complex radiologic and pathologic imaging data, maintaining compliance with regulations such as HIPAA, GDPR, and 21 CFR Part 11 across clinical research networks.

At a health-system scale, the implementation of the National Health Service (NHS) Federated Data Platform (FDP) in the United Kingdom illustrates how multimodal data can be connected across nationwide healthcare networks. Rather than constructing a centralised national database, an approach that faced challenges in historical initiatives due to privacy and governance concerns, the FDP utilises a federated deployment model.

Under this federated architecture, patient data remains in situ within individual NHS Acute Trusts, Mental Health Trusts and Integrated Care Boards (ICBs), with each organisation maintaining administrative control over its local platform instance. Cross-organisational analytical query capabilities are achieved through a shared data ontology, enabling near-real-time data access without central physical duplication of patient records. The platform targets core operational areas: elective care recovery, vaccination management, care coordination (such as utilising the OPTICA module for safe discharge planning), supply chain optimisation, and population health risk stratification. The FDP provides the operational backbone to link clinical EHR records with Genomics England, supporting routine whole genome sequencing (WGS) for paediatric rare diseases and oncology, while interfacing with the national NHS Genomic AI Network.

As multimodal AI models transition from static algorithms to continuously adaptive systems, regulatory oversight frameworks must adapt accordingly. The United States Food and Drug Administration (FDA) has introduced Predetermined Change Control Plans (PCCP) to govern artificial intelligence and machine learning-enabled medical devices.

Under a PCCP framework, device manufacturers outline planned post-market algorithmic modifications, such as iterative retraining on updated multi-omic or demographic datasets, alongside specific protocol validation methodologies to prevent algorithmic drift or bias. This regulatory mechanism allows adaptive multimodal models to update continuously within pre-approved safety boundaries without requiring a new premarket notification or approval for every iteration.

Technical Challenges, Structural Limitations and Clinical Translation

Despite technical progress, deploying multi-modal, multi-omic, multi-model AI systems in clinical environments introduces operational challenges.

Clinical data generation is sparse, asynchronous, and heterogeneous. Diagnostic workups vary widely across individual patients; a patient record may contain high-resolution MRI scans and EHR narratives but lack single-cell transcriptomics or genomic sequencing data. Multimodal architectures must incorporate missing-modality imputation techniques or masked autoencoders to maintain consistent predictions when specific input streams are absent. Furthermore, federated data environments remain vulnerable to upstream data quality issues. Errors, missing fields, or non-standardised clinical terms in primary Electronic Patient Records (EPRs) propagate directly into integrated AI models, making data cleaning and standardisation at the EPR interface essential prior to analytical platform ingestion.

Integrating multi-omic and clinical datasets also introduces risks related to latent confounding variables. Deep neural networks can identify subtle statistical correlations, but they may inadvertently base predictions on clinically irrelevant factors. Robustness audits of clinical machine learning pipelines highlight this risk. For example, in computational pipelines designed to score therapeutic candidates for cell replacement or beta-cell reprogramming, models integrating biological and clinical features can become heavily confounded by patient age. Systematic evaluation reveals that such pipelines may assign substantially higher candidacy scores to older patient tertiles (e.g., mean scores of 0.356 in the youngest tertile versus 0.693 in the oldest tertile) due to underlying age-correlated clinical variables rather than target cell biology.

Ablation studies further indicate that introducing synthetic transcriptomic features does not automatically yield improvements in predictive AUC over classical, well-balanced models like class-weighted logistic regression. Machine learning models operating on complex tabular or omic datasets must undergo pre-submission robustness audits, bootstrap confidence interval validation, failure case characterisation and counterfactual testing to prevent demographic bias.

Translating multi-omic and AI insights into frontline primary care introduces operational workflow challenges. General practitioners often operate within brief consultation windows (such as 10-minute appointments), making raw genomic outputs or complex multi-omic risk scores impractical to review directly.

Automated Clinical Decision Support (CDS) tools are required to translate complex model outputs into concise clinical recommendations. Additionally, realising the benefits of pharmacogenomics requires workforce up-skilling. Pharmacists at the point of care must be equipped to interpret pharmacogenomic indicators to adjust drug choices and dosing, reducing adverse reactions. Frameworks such as the NHS Pharmacy Genomics Workforce Strategy reflect the systemic training required to integrate multi-omic AI insights into routine community healthcare.

Synthesis and Strategic Outlook

The convergence of multi-modal data collection, multi-omic profiling and foundational multi-model architectures represents a transition in healthcare technology. Moving beyond isolated diagnostic streams enables integrative disease profiling, accurate risk stratification, and zero-shot therapeutic discovery across complex conditions.

Advancing this paradigm requires coordinated progress across technical, structural, and operational dimensions:

Architectural developments must emphasize feature-space graph networks and graph foundation models (such as SynOmics and TxGNN) that explicitly represent cross-omic molecular interactions and multi-hop biological pathways. In parallel, foundational model scaling must continue expanding the capacity of biological language models (such as Evo2 and HyenaDNA) and multimodal generalist platforms to process long genomic sequences and complex clinical data streams.

Enterprise infrastructure demands the adoption of non-custodial, ontology-driven federated platforms (such as the NHS FDP) supported by high-performance multi-dimensional array storage engines (such as TileDB) to securely connect clinical and multi-omic data across health systems. Finally, successful clinical translation relies on rigorous evaluation protocols to identify algorithmic bias and age confounding, alongside adaptive regulatory mechanisms (such as FDA PCCP guidance) and clinical workforce up-skilling to ensure AI-driven recommendations are safe, interpretable, and seamlessly integrated into patient care workflows.

Through these aligned advancements, healthcare technology shifts from reactive, population-average approaches to a proactive, precise, and systemically integrated model of medicine.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics